Gerresheimer's Liquidity Crunch Intensifies as Auditors Scrutinize Books
14.04.2026 - 14:43:12 | boerse-global.de
The immediate survival of pharmaceutical packaging group Gerresheimer now depends on the goodwill of its lenders. The company is in technical default on its credit agreements, forcing management into urgent negotiations to secure extensions and prevent a termination of its credit lines. This financial distress stems from a deepening accounting scandal that has left the firm without an audited annual report and ejected from Germany's SDAX index.
Regulators are turning up the heat. Germany's Federal Financial Supervisory Authority, BaFin, is investigating potential revenue recognition errors and examining questionable leasing liabilities worth €65.5 million. The probe also targets capitalized development costs of nearly €30 million. The audit watchdog APAS has now opened professional misconduct proceedings against auditor KPMG, which gave an unqualified sign-off on the faulty 2024 accounts shortly after taking over the mandate from Deloitte.
At the heart of the crisis are improper "bill-and-hold" agreements. Auditors identified €35 million in fictitious revenues for 2024 alone, booked prematurely in violation of IFRS standards. To shed light on the full extent of the issues, a second auditing firm has been tasked with examining the company's books through May 2025.
Should investors sell immediately? Or is it worth buying Gerresheimer?
The operational fallout is severe. Gerresheimer is pulling a strategic emergency brake, initiating the sale of its US-based Centor segment, a process being managed by Morgan Stanley. The company also plans to shutter its glass factory in Chicago Heights by the end of 2026, shifting some production to Italy and India to support margins. Furthermore, massive non-cash impairments of up to €240 million are expected, primarily related to technology projects at Sensile Medical AG and a facility in Chicago.
For investors, the calendar is barren. The annual financial statement is delayed until at least June. No dates are set for the first-quarter report or the 2026 Annual General Meeting. The only fixed point of reference is the half-year report scheduled for July 14, 2026.
The SDAX expulsion, effective April 10, has triggered forced selling by index-tracking funds, exacerbating the share price collapse. The stock currently trades at just €17.09, marking a 38% plunge since the start of the year and a staggering 68% decline over the past twelve months from a high above €80.
Management continues to cite a conditional forecast for adjusted revenue between €2.3 and €2.4 billion. However, this outlook is explicitly contingent on successful credit negotiations and is currently viewed with deep skepticism. The company's future now hinges on two events: the delivery of a clean audit in June and securing the continued support of its banking partners. Until then, every financial metric remains unverified and the stock lacks any reliable basis for valuation.
Ad
Gerresheimer Stock: New Analysis - 14 April
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Gerresheimers Aktien ein!
Für. Immer. Kostenlos.
